NVS : Summary for Novartis AG Common Stock - Yahoo Finance

U.S. Markets close in 5 hrs 54 mins

Novartis AG (NVS)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
67.07-1.55 (-2.26%)
As of 10:05 AM EST. Market open.
People also watch:
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close68.62
Open67.05
Bid67.08 x 500
Ask67.09 x 200
Day's Range66.93 - 67.22
52 Week Range66.93 - 88.49
Volume878,562
Avg. Volume2,760,047
Market Cap160.61B
Beta0.71
PE Ratio (TTM)23.65
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.94%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Kiplinger23 hours ago

    7 Stocks for Retirees to Beat the Market in 2017

    Forget politics. Instead, look for reasonably priced companies with competitive advantages.

  • Sanofi May Battle Johnson & Johnson For European Biotech Actelion
    Investor's Business Daily2 days ago

    Sanofi May Battle Johnson & Johnson For European Biotech Actelion

    Sanofi is mulling a bid for Actelion, which has an offer from Johnson & Johnson on the table.

  • Reuters2 days ago

    Novartis' drug tops chemotherapy in untreated lung cancer patients

    Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy. Novartis' drug also has conditional approval as a second-line treatment in Europe.